Iron Deficiency Anemia: IV Iron Formulations and Indications
Diagnosis: Ferritin Thresholds and Confounders
Serum ferritin remains the most useful initial test, with a threshold below 30 ng/mL providing sensitivity of 92% and specificity of 98% for iron deficiency in otherwise healthy adults. However, ferritin is an acute-phase reactant that rises with inflammation, infection, liver disease, and malignancy. In inflammatory states, a ferritin below 100 ng/mL combined with transferrin saturation below 20% identifies iron deficiency with reasonable accuracy. Soluble transferrin receptor (sTfR) and the sTfR/log ferritin index are less affected by inflammation and improve diagnostic accuracy in complex patients (AUC 0.95 versus 0.85 for ferritin alone). Reticulocyte hemoglobin content (CHr below 28 pg) provides a real-time snapshot of iron-restricted erythropoiesis.
Oral Iron: Optimization Strategies
Ferrous sulfate 325 mg (65 mg elemental iron) every other day is now preferred over daily or multiple daily dosing, based on the landmark hepcidin studies by Moretti et al. (2015) showing that alternate-day dosing increases fractional iron absorption by 34% compared to twice-daily dosing while reducing GI side effects. Absorption is maximized by taking on an empty stomach with vitamin C (200 mg). GI side effects affect 30-50% of patients on conventional regimens, driving non-adherence. Ferric maltol (30 mg twice daily) offers improved tolerability with comparable efficacy, achieving hemoglobin normalization in 65% of IBD patients at 12 weeks in the AEGIS study.
Indications for Intravenous Iron
IV iron is indicated for oral iron intolerance or nonadherence, malabsorption (celiac disease, post-bariatric surgery, IBD), ongoing blood loss exceeding oral repletion capacity, hemoglobin below 7 g/dL requiring rapid correction, chronic kidney disease on ESA therapy, and heart failure with iron deficiency (ferritin below 100 or ferritin 100-299 with TSAT below 20%). The AFFIRM-AHF trial demonstrated that IV ferric carboxymaltose (FCM) reduced recurrent heart failure hospitalizations by 26% (RR 0.74, 95% CI 0.58-0.94) in patients with HFrEF and iron deficiency, even without anemia.
Sponsored
IV Iron Formulations: Comparative Guide
Ferric carboxymaltose (Injectafer) allows up to 750 mg per infusion (15 mg/kg) in 15-30 minutes, with 2 doses 7 days apart for total repletion up to 1,500 mg. Ferric derisomaltose (Monoferric) permits single-session repletion up to 1,000-1,500 mg in 20-60 minutes, making it the most convenient option. Iron sucrose (Venofer) requires multiple 200-300 mg doses over 2-3 weeks and is the most established agent in CKD. Low-molecular-weight iron dextran allows single-dose total repletion (up to 1,000 mg in 60 minutes) but carries a slightly higher anaphylaxis risk. The rate of serious infusion reactions across all modern IV iron formulations is 0.02-0.04% per infusion, comparable to IV antibiotics.
Monitoring and Hypophosphatemia Risk
Post-IV iron monitoring includes CBC and ferritin at 4-8 weeks (earlier measurement overestimates stores). Ferric carboxymaltose carries a unique risk of hypophosphatemia through FGF23 elevation: the PHOSPHARE-IDA trials documented hypophosphatemia (below 2 mg/dL) in 50-75% of patients receiving FCM versus 8% with ferric derisomaltose. Symptomatic hypophosphatemia (fatigue, bone pain, myopathy) is clinically significant in 10-15% and can persist for weeks. Phosphate monitoring at 2 weeks post-infusion is recommended for FCM, particularly with repeated dosing. Ferric derisomaltose is preferred when repeated infusions are anticipated or in patients at risk for phosphate depletion (vitamin D deficiency, malabsorption).
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.